The commercial real estate needs of life sciences companies (pharma, biotech, medical device) are both varied and complex. While start-ups tend to seek small generic lab space, more established enterprises typically require large build-to-suit spaces in which to house their state-of-the-art production facilities. Similarly diverse are life sciences landlords, who range in size from large REITs to real estate developers and even smaller building owners looking to convert their buildings into lab space in the low vacancy rate areas where such tenants tend to cluster. 

As we head into Q2, now is a good time to remind California employers of their obligation to provide harassment prevention training to employees during 2019.

The Massachusetts Paid Family and Medical Leave Act (PFML) will provide Massachusetts employees paid family and medical leave beginning January 1, 2021. Although the final regulations supporting the PFML are still being developed, employers should familiarize themselves with the PFML’s key provisions, including specific employer compliance obligations which will begin as early as July 1, 2019. 

In an earlier post, we explored some of the key issues in a contract manufacturing agreement from the perspective of the drug developer. However, Outside GC frequently represents outsourced manufacturers, too. The knowledge we’ve gained from working on both sides of the table enables us to effectively and efficiently negotiate agreements that satisfy both parties.

As a start-up tech company, you’ve likely poured hundreds of hours into the development and testing of a marketable product, and have pitched your idea to countless investor groups and prospective customers. After your product is launched and customers are being signed up, a whole new set of concerns will present themselves. For start-ups targeting customers in the healthcare industry, these concerns will likely include the adoption of critical compliance and risk mitigation protocols mandated by HIPAA for the so-called “Business Associates” of “Covered Entities.”